
Psychemedics Corporation PMD
Quarterly report 2024-Q3
added 11-12-2024
Psychemedics Corporation Book Value 2011-2026 | PMD
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Psychemedics Corporation
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.67 M | 10.8 M | 12.2 M | 12.5 M | 16.8 M | 18.7 M | 18.6 M | 15.6 M | 11.7 M | 12.8 M | 12.3 M | 11.2 M | 11 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 18.7 M | 6.67 M | 13.2 M |
Quarterly Book Value Psychemedics Corporation
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.45 M | 5.74 M | 6.28 M | 6.67 M | 7.43 M | 9.13 M | 10.2 M | 10.8 M | 11.7 M | 11.9 M | 12.5 M | 12.2 M | 14 M | 13.1 M | 12.8 M | 12.5 M | 12.5 M | 12.5 M | 12.5 M | 16.8 M | 16.8 M | 16.8 M | 16.8 M | 18.7 M | 18.7 M | 18.7 M | 18.7 M | 18.6 M | 18.6 M | 18.6 M | 18.6 M | 15.6 M | 15.6 M | 15.6 M | 15.6 M | 11.7 M | 11.7 M | 11.7 M | 11.7 M | 12.8 M | 12.8 M | 12.8 M | 12.8 M | 12.3 M | 12.3 M | 12.3 M | 12.3 M | 11.2 M | 11.2 M | 11.2 M | 11.2 M | 11 M | 11 M | 11 M | 11 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 18.7 M | 5.45 M | 13 M |
Book Value of other stocks in the Diagnostics research industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
77.2 M | - | -6.23 % | $ 30.6 M | ||
|
Co-Diagnostics
CODX
|
20.6 M | $ 1.51 | -1.63 % | $ 2.01 M | ||
|
Agilent Technologies
A
|
5.39 B | $ 112.63 | 1.19 % | $ 34.2 B | ||
|
Akumin
AKU
|
141 M | - | -17.87 % | $ 25.9 M | ||
|
Biocept
BIOC
|
8.86 M | - | -13.05 % | $ 7.29 M | ||
|
Aspira Women's Health
AWH
|
-6.93 M | - | -6.19 % | $ 10.5 M | ||
|
Accelerate Diagnostics
AXDX
|
-22.3 M | - | -61.36 % | $ 2.46 M | ||
|
CareDx, Inc
CDNA
|
303 M | $ 20.46 | -1.63 % | $ 1.09 B | ||
|
Fulgent Genetics
FLGT
|
1.13 B | $ 14.99 | 1.28 % | $ 453 M | ||
|
Chembio Diagnostics
CEMI
|
17.8 M | - | 0.22 % | $ 16.8 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
16.7 M | - | - | $ 562 M | ||
|
Check-Cap Ltd.
CHEK
|
-1.45 M | - | - | $ 9.42 M | ||
|
Castle Biosciences
CSTL
|
456 M | $ 24.5 | 1.07 % | $ 681 M | ||
|
Illumina
ILMN
|
6.3 B | $ 124.54 | 3.46 % | $ 19.8 B | ||
|
DermTech
DMTK
|
57.2 M | - | -11.32 % | $ 2.94 M | ||
|
Global Cord Blood Corporation
CO
|
4.88 B | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
132 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
16.4 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
548 M | - | 0.12 % | $ 80.1 M | ||
|
Charles River Laboratories International
CRL
|
3.21 B | $ 163.04 | -0.45 % | $ 8.08 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
1.32 B | - | - | $ 10.7 B | ||
|
Enzo Biochem
ENZ
|
56.1 M | - | -8.98 % | $ 14.8 K | ||
|
Exact Sciences Corporation
EXAS
|
2.4 B | - | - | $ 19.8 B | ||
|
Guardant Health
GH
|
-99.3 M | $ 84.06 | 0.78 % | $ 10.5 B | ||
|
Burning Rock Biotech Limited
BNR
|
1.85 B | $ 17.07 | 5.11 % | $ 180 M | ||
|
Lantheus Holdings
LNTH
|
1.09 B | $ 80.71 | -0.57 % | $ 5.45 B | ||
|
Medpace Holdings
MEDP
|
459 M | $ 416.76 | 0.77 % | $ 12 B | ||
|
NeoGenomics
NEO
|
837 M | $ 8.97 | 0.11 % | $ 1.15 B | ||
|
National Research Corporation
NRC
|
14 M | $ 16.7 | 0.94 % | $ 374 M | ||
|
Koninklijke Philips N.V.
PHG
|
11 B | $ 26.05 | 1.84 % | $ 20 B | ||
|
Personalis
PSNL
|
203 M | $ 5.1 | 1.19 % | $ 302 M | ||
|
Heska Corporation
HSKA
|
422 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
5.39 M | - | -20.0 % | $ 1.06 M | ||
|
Senseonics Holdings
SENS
|
61 M | $ 6.37 | -0.86 % | $ 266 M | ||
|
Interpace Biosciences
IDXG
|
22.4 M | $ 1.99 | 2.9 % | $ 8.8 M | ||
|
QIAGEN N.V.
QGEN
|
6.15 B | - | - | $ 10.6 B | ||
|
Biomerica
BMRA
|
4.1 M | $ 2.16 | - | $ 4.96 M | ||
|
Thermo Fisher Scientific
TMO
|
110 B | $ 466.78 | 0.11 % | $ 176 B | ||
|
ICON Public Limited Company
ICLR
|
9.52 B | $ 114.34 | -1.58 % | $ 9.43 B | ||
|
Trinity Biotech plc
TRIB
|
-35.2 M | $ 0.62 | 3.33 % | $ 61.9 M | ||
|
Laboratory Corporation of America Holdings
LH
|
8.64 B | $ 256.62 | -0.2 % | $ 21.4 B | ||
|
Twist Bioscience Corporation
TWST
|
473 M | $ 57.9 | 2.12 % | $ 3.46 B | ||
|
Celcuity
CELC
|
101 M | $ 117.65 | -1.14 % | $ 5.5 B | ||
|
Motus GI Holdings
MOTS
|
2.69 M | - | -34.28 % | $ 263 K | ||
|
Neogen Corporation
NEOG
|
2.07 B | $ 9.06 | 0.55 % | $ 1.97 B | ||
|
Invitae Corporation
NVTA
|
102 M | - | - | $ 21.2 M | ||
|
Myriad Genetics
MYGN
|
368 M | $ 4.72 | 0.85 % | $ 437 M | ||
|
OpGen
OPGN
|
7.38 M | - | -16.95 % | $ 1.54 M | ||
|
Natera
NTRA
|
706 M | $ 199.85 | 2.62 % | $ 19.7 B | ||
|
Quest Diagnostics Incorporated
DGX
|
16.2 B | $ 190.49 | 0.59 % | $ 21.1 B |